Intratumoral injection of anlotinib hydrogel enhances antitumor effects and reduces toxicity in mouse model of lung cancer

References

• Bermejo-Velasco D, Dou W, Heerschap A, et al. (2018). Injectable hyaluronic acid hydrogels with the capacity for magnetic resonance imaging. Carbohydr Polym 197:641–8.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424.
   PubMed Web of Science ®Google Scholar
• Chen XZ. (2019). Anlotinib for refractory advanced non-small cell lung cancer in China. JAMA Oncol 5:116–7.
   Web of Science ®Google Scholar
• Han B, Li K, Wang Q, et al. (2018a). Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol 4:1569–75.
   PubMed Web of Science ®Google Scholar
• Han B, Li K, Zhao Y, et al. (2018b). Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer 118:654–61.
   PubMed Web of Science ®Google Scholar
• He C, Wu T, Hao Y. (2018). Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway. Biochem Biophys Res Commun 503:3093–9.
   PubMed Web of Science ®Google Scholar
• Kurisawa M, Chung JE, Yang YY, et al. (2005). Injectable biodegradable hydrogels composed of hyaluronic acid–tyramine conjugates for drug delivery and tissue engineering. Chem Commun 34: 4312–4.
   Google Scholar
• Lee F, Chung JE, Kurisawa M. (2008). An injectable enzymatically crosslinked hyaluronic acid–tyramine hydrogel system with independent tuning of mechanical strength and gelation rate. Soft Matter 4:880.
   PubMed Web of Science ®Google Scholar
• Liang H-KT, Lai X-S, Wei M-F, et al. (2018). Intratumoral injection of thermogelling and sustained-release carboplatin-loaded hydrogel simplifies the administration and remains the synergistic effect with radiotherapy for mice gliomas. Biomaterials 151:38–52.
   PubMed Web of Science ®Google Scholar
• Lin B, Song X, Yang D, et al. (2018). Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene 654:77–86.
   PubMed Web of Science ®Google Scholar
• Paduch R. (2016). The role of lymphangiogenesis and angiogenesis in tumor metastasis. Cell Oncol (Dordr) 39:397–410.
   PubMed Web of Science ®Google Scholar
• Ruan X, Shi X, Dong Q, et al. (2019). Antitumor effects of anlotinib in thyroid cancer. Endocr Relat Cancer 26:153–64.
   PubMed Web of Science ®Google Scholar
• Saravanakumar G, Choi KY, Yoon HY, et al. (2010). Hydrotropic hyaluronic acid conjugates: synthesis, characterization, and implications as a carrier of paclitaxel. Int J Pharm 394:154–61.
   PubMed Web of Science ®Google Scholar
• Shen G, Zheng F, Ren D, et al. (2018). Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol 11:120.
   PubMed Web of Science ®Google Scholar
• Si X, Zhang L, Wang H, et al. (2018). Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. Lung Cancer 122:32–7.
   PubMed Web of Science ®Google Scholar
• Si X, Zhang L, Wang H, et al. (2019). Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: experiences in ALTER-0303. Thorac Cancer 10:551–6.
   PubMed Web of Science ®Google Scholar
• Sun Y, Niu W, Du F, et al. (2016). Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol 9:105.
   PubMed Web of Science ®Google Scholar
• Tang J, Wang N, Wu JBo, et al. (2019). Synergistic effect and reduced toxicity by intratumoral injection of cytarabine-loaded hyaluronic acid hydrogel conjugates combined with radiotherapy on lung cancer. Invest New Drugs 37:1146–57.
   PubMed Web of Science ®Google Scholar
• Tongbai T, McDermott S, Kiranantawat N, et al. (2019). Non-diagnostic CT-guided percutaneous needle biopsy of the lung: predictive factors and final diagnoses. Korean J Radiol 20:1515–26.
   PubMed Web of Science ®Google Scholar
• Torre LA, Siegel RL, Jemal A. (2016). Lung cancer statistics. Adv Exp Med Biol 893:1–19.
   PubMed Web of Science ®Google Scholar
• Ueda K, Akiba J, Ogasawara S, et al. (2016). Growth inhibitory effect of an injectable hyaluronic acid–tyramine hydrogels incorporating human natural interferon-α and sorafenib on renal cell carcinoma cells. Acta Biomater 29:103–11.
   PubMed Web of Science ®Google Scholar
• Viallard C, Larrivee B. (2017). Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis 20:409–26.
   PubMed Web of Science ®Google Scholar
• Wang G, Sun M, Cai Z. (2019). Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int J Cancer 145:979–93.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhong Y, Liu W, et al. (2019). Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid. Drug Deliv 26:12–22.
   PubMed Web of Science ®Google Scholar
• Xie C, Wan X, Quan H, et al. (2018). Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci 109:1207–19.
   PubMed Web of Science ®Google Scholar
• Xu K, Lee F, Gao S, et al. (2015). Hyaluronidase-incorporated hyaluronic acid–tyramine hydrogels for the sustained release of trastuzumab. J Control Release 216:47–55.
   PubMed Web of Science ®Google Scholar
• Xu K, Lee F, Gao SJ, et al. (2013). Injectable hyaluronic acid–tyramine hydrogels incorporating interferon-α2a for liver cancer therapy. J Control Release 166:203–10.
   PubMed Web of Science ®Google Scholar
• Yang L, Li J, Fu S, et al. (2019). Up-regulation of insulin-like growth factor binding protein-3 is associated with brain metastasis in lung adenocarcinoma. Mol Cells 42:321–32.
   PubMed Web of Science ®Google Scholar
• Yoon HY, Koo H, Choi KY, et al. (2012). Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy. Biomaterials 33:3980–9.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li X, Zhong N, et al. (2019). Injectable in situ dual-crosslinking hyaluronic acid and sodium alginate based hydrogels for drug release. J Biomater Sci Polym Ed 30:995–1007.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao H, Chi Y. (2018). Safety and efficacy of the S-1/temozolomide regimen in patients with metastatic neuroendocrine tumors. Neuroendocrinology 106:318–23.
   PubMed Web of Science ®Google Scholar
• Zhao T, He Y, Chen H, et al. (2017). Novel apigenin-loaded sodium hyaluronate nano-assemblies for targeting tumor cells. Carbohydr Polym 177:415–23.
   PubMed Web of Science ®Google Scholar
• Zhong C-c, Chen F, Yang J-l, et al. (2018). Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species. Acta Pharmacol Sin 39:1048–63.
   PubMed Web of Science ®Google Scholar
• Zhong L, Xu L, Liu Y, et al. (2019). Transformative hyaluronic acid-based active targeting supramolecular nanoplatform improves long circulation and enhances cellular uptake in cancer therapy. Acta Pharm Sin B 9:397–409.
   PubMed Web of Science ®Google Scholar
• Zhou M, Chen X, Zhang H, et al. (2019). China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Cancer Commun (Lond) 39:36.
   PubMed Web of Science ®Google Scholar